知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

991 records (took 0.028 seconds)

    USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLS
    32.
    发明申请
    USE OF ENTPD3 FOR IDENTIFICATION, ISOLATION, AND ENHANCING MATURE STEM CELL DERIVED INSULIN-PRODUCING CELLS 有权

    公开(公告)号：US20220296652A1

    公开(公告)日：2022-09-22

    申请号：US17704429

    申请日：2022-03-25

    Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

    Inventor： Holger A. Russ ,  Fiona Docherty

    IPC: A61K35/39 ,  C12N5/071 ,  C12N5/0735

    Abstract: Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and/or curing diabetes, for example type-1 diabetes.

    Universal donor cells
    34.
    发明授权
    Universal donor cells 有权

    公开(公告)号：US11433103B2

    公开(公告)日：2022-09-06

    申请号：US17383760

    申请日：2021-07-23

    Applicant: CRISPR THERAPEUTICS AG

    Inventor： Alireza Rezania ,  Rebeca Ramos-Zayas

    IPC: C07K14/74 ,  A61K35/39 ,  C12N5/074 ,  C12N5/071 ,  C12N5/10 ,  C12N5/16 ,  C12N5/0735

    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

    METHOD FOR SEPARATING PANCREATIC PROGENITOR CELLS
    36.
    发明申请
    METHOD FOR SEPARATING PANCREATIC PROGENITOR CELLS 有权

    公开(公告)号：US20220257666A1

    公开(公告)日：2022-08-18

    申请号：US17618241

    申请日：2020-06-26

    Applicant: The University of Tokyo

    Inventor： Atsushi MIYAJIMA ,  Ami WATANABE

    IPC: A61K35/39 ,  A61K35/545 ,  A61P3/10

    Abstract: It is an object of the present invention to provide a method for preparing or separating pancreatic progenitor cells (or a group of pancreatic progenitor cells) that do not contain undifferentiated cells and efficiently differentiate into pancreatic islet cells. More specifically, the present invention relates to: pancreatic progenitor cells that appear in the process of differentiation of stem cells into pancreatic islet cells, which are characterized in that the pancreatic progenitor cells are positive to CD82; an agent for treating blood glucose level impairment, wherein the agent comprises the pancreatic progenitor cells; and a method for preparing pancreatic progenitor cells, wherein the method comprises separating CD82-positive cells.

    PANCREATIC DIFFERENTIATION
    37.
    发明申请
    PANCREATIC DIFFERENTIATION 有权

    公开(公告)号：US20220235327A1

    公开(公告)日：2022-07-28

    申请号：US17669874

    申请日：2022-02-11

    Applicant: Vertex Pharmaceuticals Incorporated

    Inventor： George HARB ,  Lillian YE

    IPC: C12N5/071 ,  A61K35/39 ,  A61P3/10

    Abstract: In some aspects, disclosed herein are methods and compositions for generating enterochromaffin cells. In some aspects, the methods and compositions disclosed herein relate to use of an inhibitor of IL-4/JAK3 signaling pathway. In other aspects, disclosed herein are cell compositions, pharmaceutical compositions, and medical devices that relate to pancreatic cells that are generated according to the methods disclosed herein.

    UNIVERSAL DONOR CELLS
    38.
    发明申请
    UNIVERSAL DONOR CELLS 有权

    公开(公告)号：US20220204940A1

    公开(公告)日：2022-06-30

    申请号：US17566924

    申请日：2021-12-31

    Applicant: CRISPR THERAPEUTICS AG

    Inventor： Alireza Rezania ,  Valentin Sluch

    IPC: C12N5/071 ,  C07K14/475 ,  C07K14/525 ,  C07K14/74 ,  C07K14/705 ,  A61P1/18 ,  A61K35/39

    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.

Patent Agency Ranking